$3.53
0.00% yesterday
Nasdaq, Nov 27, 01:26 am CET
ISIN
US5171251003
Symbol
LRMR

Larimar Therapeutics Inc Stock price

$3.53
-0.81 18.66% 1M
+1.66 88.77% 6M
-0.34 8.79% YTD
-2.65 42.88% 1Y
+0.45 14.61% 3Y
-17.38 83.12% 5Y
-206.47 98.32% 10Y
-233.47 98.51% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.14 3.81%
ISIN
US5171251003
Symbol
LRMR
Industry

Key metrics

Basic
Market capitalization
$302.1m
Enterprise Value
$126.7m
Net debt
positive
Cash
$175.4m
Shares outstanding
85.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
85.8%
Return on Equity
-46.9%
ROCE
-98.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-139.4m | $-127.2m
EBIT
$-139.8m | $-131.1m
Net Income
$-132.0m | $-144.9m
Free Cash Flow
$-96.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-89.9% | -40.5%
EBIT
-89.5% | -44.2%
Net Income
-103.8% | -79.8%
Free Cash Flow
-64.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.1
Short interest
17.7%
Employees
65
Rev per Employee
$0.0
Show more

Is Larimar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Larimar Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Larimar Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Larimar Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Larimar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
10% 10%
-
- Research and Development Expense 122 122
113% 113%
-
-139 -139
90% 90%
-
- Depreciation and Amortization 0.34 0.34
6% 6%
-
EBIT (Operating Income) EBIT -140 -140
89% 89%
-
Net Profit -132 -132
104% 104%
-

In millions USD.

Don't miss a Thing! We will send you all news about Larimar Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Larimar Therapeutics Inc Stock News

Neutral
GlobeNewsWire
23 days ago
In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of nomlabofusp to alter FA's disease course relative to a worsening in a FACOMS natural history study r...
Neutral
PRNewsWire
about one month ago
LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inves...
Neutral
Business Wire
about one month ago
LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.
More Larimar Therapeutics Inc News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.

Head office United States
CEO Carole Ben-Maimon
Employees 65
Founded 2005
Website larimartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today